Invention Grant
- Patent Title: Quantitative methods and kits for providing reproducible IHC4 scores
-
Application No.: US13841887Application Date: 2013-03-15
-
Publication No.: US10408846B2Publication Date: 2019-09-10
- Inventor: Mark D. Gustavson , Jason Christiansen
- Applicant: Novartis AG
- Applicant Address: CH Basel
- Assignee: Novartis AG
- Current Assignee: Novartis AG
- Current Assignee Address: CH Basel
- Agency: Foley & Lardner LLP
- Agent Gilberto M. Villacorta
- Main IPC: G01N33/48
- IPC: G01N33/48 ; G01N33/68 ; G01N33/574 ; G01N33/74
Abstract:
The present technology relates generally to determining a risk of recurrence of disease in a cancer patient. In particular, this approach to determining a risk of recurrence involves utilizing standardized quantitative assessments of the level of biomarker expression selected from estrogen receptor (ER), progesterone receptor (PR), human epidermal growth factor receptor 2 (HER2) and Ki-67 (Ki67) in a patient's tumor to determine the risk of recurrence, thereby allowing a caretaker to determine the best course of treatment for the patient.
Public/Granted literature
- US20130310267A1 QUANTITATIVE METHODS AND KITS FOR PROVIDING REPRODUCIBLE IHC4 SCORES Public/Granted day:2013-11-21
Information query
